Emergent Broadens Bioterror Offering In $125m Sanofi Smallpox Vaccine Buy

Sanofi's divestment of its ACAM200 smallpox vaccine frees it to focus on "current and emerging" infectious disease jabs - while expanding Emergent BioSolutions adds to its anti-bioterror product offering.